The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMPN 2026 | Emerging therapeutic strategies and future directions in MPNs
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the emerging landscape of myeloproliferative neoplasms (MPNs), highlighting the potential of targeted therapies, such as anti-calreticulin antibodies and novel JAK inhibitors. Dr Masarova also emphasizes the importance of addressing anemia in MPN patients, with agents like luspatercept showing promise, and notes that the field will likely evolve towards exploring treatment-free remissions. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
